Abstract
Main conclusion
The HRA2pl peptide expressed by transient transformation in N. tabacum plants is capable of inhibiting the binding of the human metapneumovirus to HEp-2 cells at the fusion stage.
Human metapneumovirus (hMPV) is an agent responsible for acute respiratory infections that mainly affects children under 3 years, the elderly and immunocompromised patients. In children younger than 5 years, respiratory tract infections account for 20 % of deaths worldwide. However, there is currently no treatment or vaccine available against hMPV. The production of a safe, efficient and low cost treatment against this virus is a current challenge. Plants provide a system for recombinant protein production that is cost effective and is easier to scale up to an industrial level than other platforms; in addition, the plant tissue may be used as raw food, dried or, alternatively, proteins may be partially or fully purified and administered in aerosol or capsules as dry powder. In this study, we designed a gene expressing an antiviral peptide against hMPV based on the heptad repeat A domain of the F protein of the virus. We produced the recombinant peptide by a viral transient expression system (Magnifection®) in Nicotiana tabacum plants. The efficacy of this antiviral peptide was confirmed by in vitro assays in HEp-2 cell line. This is a promising result that can offer a prophylactic approach against hMPV.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alvarez ML, Topal E, Martin F, Cardineau GA (2010) Higher accumulation of F1-V fusion recombinant protein in plants after induction of protein body formation. Plant Mol Biol 72:75–89
Baker KA, Dutch RE, Lamb RA, Jardetzky TS (1999) Structural basis for paramyxovirus-mediated membrane fusion. Mol Cell 3:309–319
Boivin G, Abed Y, Pelletier G, Ruel L, Moisan D, Cote S, Peret TC, Erdman DD, Anderson LJ (2002) Virological features and clinical manifestations associated with human metapneumovirus: a new paramyxovirus responsible for acute respiratory-tract infections in all age groups. J Infect Dis 186:1330–1334
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
Daniell H, Singh ND, Mason H, Streatfield SJ (2009) Plant-made vaccine antigens and biopharmaceuticals. Trends Plant Sci 14:669–679. doi:10.1016/j.tplants.2009.09.009
Davoodi-Semiromi A, Samson N, Daniell H (2009) The green vaccine: a global strategy to combat infectious and autoimmune diseases. Hum Vaccines 5(7):488–493. doi:10.4161/hv.8247
Deffrasnes C, Hamelin ME, Prince GA, Boivin G (2008) Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus. Antimicrob Agents Ch 52(1):279–287. doi:10.1128/aac.00793-07
Eckardt-Michel J, Lorek M, Baxmann D, Grunwald T, Keil GM, Zimmer G (2008) The fusion protein of respiratory syncytial virus triggers p53-dependent apoptosis. J Virol 82(7):3236–3249. doi:10.1128/jvi.01887-07
Eckert DM, Kim PS (2001a) Design of potent inhibitors of HIV-1 entry from the gp41N-peptide region. Proc Natl Acad Sci USA 98:11187–11192. doi:10.1073/pnas.201392898
Eckert DM, Kim PS (2001b) Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 70:777–810. doi:10.1146/annurev.biochem.70.1.777
Gleba Y, Klimyuk V, Marillonnet S (2005) Magnifection—a new platform for expressing recombinant vaccines in plants. Vaccine 23(17–18):2042–2048. doi:10.1016/j.vaccine.2005.01.006
Hahn A, Wang W, Jaggi P, Dvorchik I, Ramilo O, Koranyi K, Mejias A (2013) Human metapneumovirus infections are associated with severe morbidity in hospitalized children of all ages. Epidemiol Infect 141(10):2213–2223. doi:10.1017/s0950268812002920
Hamorsky KT, Grooms-Williams TW, Husk AS, Bennett LJ, Palmer KE, Matoba N (2013) Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides. Antimicrob Agents Chemother 57(5):2076–2086. doi:10.1128/aac.02588-12
Herfst S, Fouchier RA (2008) Vaccination approaches to combat human metapneumovirus lower respiratory tract infections. J Clin Virol 41(1):49–52. doi:10.1016/j.jcv.2007.10.022
Kitanovski L, Kopriva S, Pokorn M, Dolnicar MB, Rajic V, Stefanovic M, Jazbec J (2013) Treatment of severe human metapneumovirus (hMPV) pneumonia in an immunocompromised child with oral ribavirin and IVIG. J Pediatr Hematol Oncol 35:e311–e313
Lamb RA, Paterson RG, Jardetzky TS (2006) Paramyxovirus membrane fusion: lesson from the F and HN atomic structures. Virology 344:30–37. doi:10.1016/j.virol.2005.09.007
Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr (1996) Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci USA 93(5):2186–2191
Lawless-Delmedico MK, SistaP Sen R, Moore NC, Antczak JB, White JM, Greene RJ, Leanza KC, Matthews TJ, Lambert DM (2000) Heptad repeat regions of respiratory syncytial virus F1 protein form a sixmembered coiled-coil complex. Biochem US 39:11684–11695
Marillonnet S, Giritch A, Gils M, Kandzia R, Klimyuk V, Gleba Y (2004) In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci USA 101(18):6852–6857. doi:10.1073/pnas.0400149101
Marillonnet S, Thoeringer C, Kandzia R, Klimyuk V, Gleba Y (2005) Systemic Agrobacterium tumefaciens-mediated transfection of viral replicons for efficient transient expression in plants. Nat Biotechnol 23(6):718–723. doi:10.1038/nbt1094
Miller SA, Tollefson S, Crowe JE Jr, Williams JV, Wright DW (2007) Examination of a fusogenic hexameric core from human metapneumovirus and identification of a potent synthetic peptide inhibitor from the heptad repeat 1 region. J Virol 81(1):141–149. doi:10.1128/jvi.01243-06
Noyola DE, Alpuche-Solis AG, Herrera-Diaz A, Soria-Guerra RE, Sanchez-Alvarado J, Lopez-Revilla R (2005) Human metapneumovirus infections in Mexico: epidemiological and clinical characteristics. J Med Microbiol (Pt 10):969–974. doi:10.1099/jmm.0.46052-0
Root MJ, Kim PS, Kay MS (2001) Protein design of an HIV-1 entry inhibitor. Science 291:884–888
Roy A, Kucukural A, Zhang Y (2010) I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc 5(4):725–738. doi:10.1038/nprot.2010.5
Russell CJ, Jardetzky TS, Lamb RA (2001) Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion. EMBO J 20(15):4024–4034. doi:10.1093/emboj/20.15.4024
Schillberg S, Twyman RM, Fischer R (2005) Opportunities for recombinant antigen and antibody expression in transgenic plants—technology assessment. Vaccine 23(15):1764–1769. doi:10.1016/j.vaccine.2004.11.002
Streatfield SJ, Howard JA (2003) Plant production systems for vaccines. Expert Rev vaccines 2(6):763–775. doi:10.1586/14760584.2.6.763
van den Hoogen BG, de Jong JC, Groen J, Kuiken T, de Groot R, Fouchier RA, Osterhaus AD (2001) A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 7(6):719–724. doi:10.1038/89098
van den Hoogen BG, Bestebroer TM, Osterhaus AD, Fouchier RA (2002) Analysis of the genomic sequence of a human metapneumovirus. Virology 295(1):119–132. doi:10.1006/viro.2001.1355
van den Hoogen BG, Herfst S, Sprong L, Cane PA, Forleo-Neto E, de Swart RL, Osterhaus AD, Fouchier RA (2004) Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis 10(4):658–666. doi:10.3201/eid1004.030393
Wang XJ, Bai YD, Zhang GZ, Zhao JX, Wang M, Gao GF (2005) Structure and function study of paramyxovirus fusion protein heptad repeat peptides. Arch Biochem Biophys 436:316–322. doi:10.1016/j.abb.2005.02.004
WHO (2013) http://www.who.int/vaccine_research/diseases/ari/en/
Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ (1994) Peptides corresponding to a predictive-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 91:9770–9774
Yao Q, Compans RW (1996) Peptides corresponding to the heptad repeat sequence of human parainfluenza virus fusion protein are potent inhibitors of virus infection. Virology 223(1):103–112. doi:10.1006/viro.1996.0459
Yusibov V, Mett V, Mett V, Davidson C, Musiychuk K, Gilliam S, Farese A, Macvittie T, Mann D (2005) Peptide-based candidate vaccine against respiratory syncytial virus. Vaccine 23(17–18):2261–2265. doi:10.1016/j.vaccine.2005.01.039
Zeitlin L, Bohorov O, Bohorova N, Hiatt A, Kim do H, Pauly MH, Velasco J, Whaley KJ, Barnard DL, Bates JT, Crowe JE Jr, Piedra PA, Gilbert BE (2013) Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model. mAbs 5(2):263–269. doi:10.4161/mabs.23281
Acknowledgments
We would like to acknowledge Dr. Lara-González for his technical assistance. We also thank CONACyT Mexico for the Grant 154790 and Scholarship 332439, granted to Márquez-Escobar for her Ph.D. studies.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Márquez-Escobar, V.A., Tirado-Mendoza, R., Noyola, D.E. et al. HRA2pl peptide: a fusion inhibitor for human metapneumovirus produced in tobacco plants by transient transformation. Planta 242, 69–76 (2015). https://doi.org/10.1007/s00425-015-2277-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00425-015-2277-5